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ABSTRACT
Introduction. Optimal management of soft tissue sarcoma
(STS) remains a challenge. A nationwide survey assessed
the quality of STS care in the Netherlands, thereby aiming
to identify potentialities for improvement through more
centralized disease management.
Methods. From the Netherlands Cancer Registry (NCR),
data were obtained on 3317 adult STS patients (excluding
gastrointestinal stromal tumor, GIST) diagnosed in
2006–2011. Logistic regression models were employed to
compare outcomes on selected clinical indicators reflecting
prevailing STS guidelines between high-volume (C10
resections annually) and low-volume (\10 resections)
hospitals, between academic and general hospitals, and
between sarcoma research centers and other hospitals,
adjusted for case mix. Analyses were performed on
imputed datasets (m = 50), generated through multiple
imputations by chained equations.
Results. Overall, 89% of patients underwent surgical
resection. Resection status remained unknown in 24% (ex-
cluding those with metastasized disease), and grade was not
documented for one-third of tumors. Microscopic residual
disease was detected in 20% with an increased risk for older
patients, larger and deeply located tumors, and those located
in the (retro)peritoneum or upper extremity. Almost half of
patients with an R1 resection received adjuvant radiotherapy.
Following adjustment for case mix factors, patients treated in
high-volume hospitals less often had macroscopic residual
disease (R2 resection; adjusted odds ratio: 0.54). A strongly
skewed distribution of surgical volumes was observed.
Conclusions. These survey results indicate a potential for
improving Dutch STS care. More centralized sarcoma
management should improve definitive pathology reporting
on tumor characteristics, adherence to treatment guidelines
and overall disease outcome.
Soft tissue sarcomas (STS) form a heterogeneous group
of tumors deriving from mesenchymal progenitor cells,
often showing differentiation towards different mesenchy-
mal cells (e.g., fibrous tissue, adipose tissue, smooth and
striated muscle). The etiology remains unknown. They
account for 1% of all malignant tumors; incidence rates
increase with age and show a slight male predominance.1,2
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STS are primarily defined by the local aggressive
growth pattern and categorized in more than 50 histological
subtypes.3,4 Tumor entities vary substantially in biological
behavior and tumor grade indicate tendency for distant
metastasis, mainly to the lungs.5,6 Approximately 25% of
STS patients develop distant metastases, whereas lym-
phogenic spread is very rare, affecting only 2–3% of all
STS patients.7–9 Besides STS subtype and grade, studies
have identified anatomic site, tumor stage, size, and depth
as predictors for survival.10 These parameters are included
in several nomograms to estimate prognosis regarding local
recurrence and survival.11 Hence, obtaining accurate
information on these factors is crucial for formulating a
multidisciplinary treatment plan.
The diverse presentation and localization of STS con-
tribute to the challenges for optimal patient care. Timely
diagnosis, for instance, may be difficult given the benign to
malignant ratio of soft tissue tumors that has been esti-
mated as 100:1. Furthermore, because of their rarity,
physicians seldom encounter STS patients in their practice.
Even if recognized as such, the complexities in the diag-
nostic workup and treatment of STS require adequate
expertise and organization.7
Studies have emphasized the importance of guideline
adherence in STS care as it results in better patient out-
comes.12–14 In the Netherlands, national sarcoma
guidelines were established in 1993, with updates in 2003
and 2011.15 Key recommendations (which became
affirmed after our study period through the international
guidelines issued by the European Society for Medical
Oncology, ESMO) concerned the adequate pathology
reporting of the main prognostic sarcoma characteristics,
complete diagnostic workup of large ([5 cm), deeply
located STS (imaging supplemented with pathologic
examination) and the use of adjuvant radiotherapy after R1
resection (microscopic residual disease) or tumor spill.16–18
The purpose of this nationwide survey was to acquire
insight of the performance of hospitals on STS care (ex-
cluding gastrointestinal stromal tumor, GIST), thereby
identifying reference points for furthering quality of sar-
coma care. In addition the potential improvement due to
centralization of STS care was explored by comparing
performance between high- and low-volume hospitals,
academic centers versus general hospitals, and sarcoma
research centers versus other hospitals.
PATIENTS AND METHODS
Database
The Netherlands Cancer Registry (NCR), founded in
1989, includes all newly diagnosed malignancies, currently
covering 17 million inhabitants. The main source of
notification is the nationwide network and registry of histo-
and cytopathology (www.palga.nl) and case ascertainment
was achieved by linkage with the central hospital discharge
registry. Upon notification, registrars gather data on patient
and tumor characteristics and primary treatment modalities
by extracting information directly from the hospital files.
The NCR reports on national cancer incidence, prevalence,
survival and mortality (www.cijfersoverkanker.nl). Con-
sent for the design, data abstraction process, as well as
storage protocols for this study was obtained from the
supervisory committee of the NCR.
NCR data include patients’ age at diagnosis, histological
subtype of sarcoma on the basis of the World Health
Organization (WHO) classification 2002, and tumor grade
according to the grading system of the French Federation
of Cancer Centers (FNCLCC) Sarcoma Group.4,19 Primary
sites are translated to ICD-O topography codes and tumor
stage (depth and size) is recorded according to the TNM
system of the International Union Against Cancer (UICC)
supplemented with the Extent of Disease code of the
American Surveillance, Epidemiology and End Results
(SEER) program if available.20–23 Therapy is coded in
sequence of administration, with codes differentiating
between treatment modalities (surgery, radiotherapy, sys-
temic therapy). In case of surgical treatment, date of
resection and residual disease status are recorded.
For this study, data were retrieved on adult STS patients
(C18 years) diagnosed during the period 2006–2011,
excluding Kaposi sarcoma, GIST, and sarcoma of the skin
(Supplementary Table 1). Hospitals performing sarcoma
surgery were classified according to their mean annual
number of resections over the total study period as either
high-volume (C10 resections) or low-volume (\10 resec-
tions) and in addition hospital type (general vs. academic
hospitals) and sarcoma research centers versus other hos-
pitals. Research centers were characterized by participation
in the European Organization for Research and Treatment
of Cancer (EORTC) sarcoma group, which amongst others
implies expertise of dedicated multidisciplinary sarcoma
teams and centralized pathology review. These centers are
Netherlands Cancer Institute Amsterdam, University
Medical Center Rotterdam, University Medical Center
Groningen, University Medical Center Nijmegen, and
University Medical Center Leiden.
Clinical Indicators
Guideline adherence was evaluated with indicators
reflecting quality of STS care and for which data were
available in the NCR. The quality of pathology reports was
determined by the availability of information on sarcoma
subtype, grade, and assessment of residual disease status
after surgery.24 In assessing the reports on grading, we
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excluded sarcoma subtypes that are not graded by defini-
tion or for which grading was not recommended: MPNST,
angiosarcoma, extraskeletal myxoid chondrosarcoma,
alveolar soft part sarcoma, clear cell sarcoma, and epithe-
lioid sarcoma.19 Histomorphological codes M8800–M8806
were considered sarcoma lacking specific subtyping, and
the availability of grade was assessed separately in the
subgroup of liposarcoma (excluding well-differentiated
tumors), fibrosarcoma, and leiomyosarcoma. In rating
adequate reporting of residual disease, M1 disease and
retroperitoneal tumors were excluded from the analyses.
The quality of the diagnostic workup of STS was eval-
uated by estimating the proportion of possible ‘‘whoops’’
resections. Although the NCR data did not distinguish
between planned and unplanned procedures, potentially
unplanned procedures were defined as resections of either
large ([5 cm) or deep tumors (located beneath the super-
ficial fascia, or with invasion of or through the fascia)
without prior histopathologic information. In these cases,
the date of first histopathologic confirmation coincided
with the date of surgery.
In evaluating the use of adjuvant therapy, analysis was
focused on the proportion of patients receiving radiation
therapy. In particular, the prevalent guidelines recommend
provision of adjuvant radiotherapy to patients with R1
resections, irrespective of their tumors’ grade. For the
evaluation of adjuvant treatment, cases with distant disease
and retroperitoneal tumors were excluded. In addition,
overall 5-year survival rates for high-grade, nonmetasta-
sized tumors in surgically resected patients were estimated.
Statistical Analyses
Resection rates and rates of R1 resections were tabulated
by subgroups of patient and STS characteristics, and dif-
ferences for significance were tested by v2 tests. Potential
prognostic factors for R1 resections were selected for
evaluation in multivariable logistic regression on the basis
of p\ 0.1 in the univariable analyses. Odds ratios were
calculated together with 95% likelihood ratio confidence
intervals.
Performances on most clinical indicators were analyzed
as binary variables and logistic regressions were again
applied to estimate the impact of hospital types on man-
agement of STS patients. Overall survival rates and hazard
ratios were estimated in proportional hazards models. To
account for missing data, multiple imputations were per-
formed by chained equations under the assumption of
missingness being random, thereby creating 50 data sets for
each estimation. In addition to crude pooled estimates, we
also provided odds and hazard ratios based on the imputed
data adjusted for relevant case mix factors. All tests were
two-sided and p\ 0.05 was considered statistically
significant. Statistical analyses were performed using Stata
(version 14.0; StataCorp, College Station, TX).
RESULTS
Patient and Tumor Characteristics
In total 3317 patients, 1830 men (55%) and 1487 women
(45%), were diagnosed with a primary STS (Table 1). The
median age was 63 (interquartile range 50–75) years; 47%
was[65 years. Tumors were mostly located in the extrem-
ities (47%), e.g., lower extremity (34%) and upper extremity
(13%), followed by the trunk (36%), head and neck region
(11%), and retroperitoneum (7%). The majority of tumors
were high-grade (54%). In more than a quarter of cases
(28%), no information on grade could be retrieved from the
pathology report. Almost one-third of STS (32%) was con-
sidered small (\5 cm), 61% larger than 5 cm, and in 7% the
tumor size could not be retrieved from the clinical or
pathology report. Superficially and deeply located tumors
were approximately evenly distributed (46 and 43%,
respectively), whereas depth was not reported in 12%.
Metastatic disease was encountered in 14%. Liposarcoma
(20%) and leiomyosarcoma (21%) comprised the most
prevalent histology (Table 2).
Most patients underwent a resection (81%). Patients
who did not underwent surgery were relatively older
(median age 69 vs. 62 years), more often a tumor in the
trunk (54 vs. 32%), and less often in the extremities (26 vs.
51%). Overall, resected tumors exhibited more favorable
characteristics: lower grade, relatively smaller, more often
superficially located and mostly localized disease. Surgery
was performed in 14% of initial stage IV disease. Forty
percent of the 1081 operated patients received radiation
therapy, whereas 191 patients received chemotherapy (7%)
(data not shown).
One-fifth of the resections were R1 resections (20%),
thereby excluding cases with macroscopic and unknown
residual disease and those primarily diagnosed with distant
disease. R1 resections occurred more often in elderly
patients and with tumors located in the (retro)peritoneum
or upper extremity and less often in the trunk and lower
extremity. In addition, surgery for larger STS and deeply
located tumors showed an elevated risk of positive resec-
tion margins. Among patients who had an R1 resection, the
proportion receiving adjuvant radiotherapy was 47%.
Hospital Characteristics
During the study period, diagnostic work and resection
of STS was performed in 96 hospitals. Among these were
eight academic hospitals and one cancer center (classified
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in the analyses as academic hospital); five of these were
considered sarcoma research centers. A strongly skewed
distribution of case volumes by hospital was observed
(Fig. 1). Overall, 12% of hospitals accounted for half of all
STS resections; this proportion decreased from 16% in
2006 to 10% in 2011. Furthermore, 75% of resections were
performed in one-third of hospitals, whereas 90% were
performed in almost two-thirds. Sarcoma research centers
represented the largest surgical volume.
Over time, no trend was detected for whether or not
patients underwent surgery in high-volume hospitals.
However, we did observe a significant trend within the
high-volume group. While the proportion of patients trea-
ted in hospitals performing a yearly total of 10–19
resections decreased from 27% in 2006 to 2% in 2011,
there was an increase for those treated in hospitals per-
forming 20 or more resections annually (p = 0.01;
Fig. 2a). Academic hospitals accounted for 46% of STS
resections, and this proportion did not show a trend over
time (Fig. 2b). In contrast, the proportion of patients trea-
ted in sarcoma research centers increased from 28 to 41%
(p\ 0.01; Fig. 2c).
TABLE 1 General characteristics and resection rates for adult patients (C18 years) diagnosed with a soft tissue sarcoma (STS) in the
Netherlands during the time period 2006–2011
Total (n = 3317) Resection (n = 2698; 81.3%) R1 resection (n = 393; 20.4%)*
n % n % p n % p
Sex 0.10 0.20
Male 1830 55.1% 1507 55.9% 205 52.2%
Female 1487 44.9% 1191 44.1% 188 47.8%
Age at diagnosis (year) \0.00 \0.00
18–49 794 23.9% 691 25.6% 85 21.6%
50–64 965 29.1% 807 29.9% 99 25.2%
65–79 1036 31.2% 823 30.5% 130 33.1%
C80 522 15.7% 377 14.0% 79 20.1%
Median (interquartile range) 63 (50–75) 62 (49–74) 66 (52–77)
Primary tumor site \0.00 \0.00
Head and neck 354 10.7% 293 10.9% 44 11.2%
Trunk 1192 35.9% 856 31.7% 98 24.9%
(Retro)peritoneum 227 6.8% 169 6.3% 39 9.9%
Extremity 1544 46.6% 1380 51.2% 212 53.9%
Upper 431 13.0% 392 14.5% 75 19.1%
Lower 1113 33.6% 988 36.6% 137 34.9%
Tumor grade \0.00 0.95
Low grade 566 17.1% 528 19.6% 76 19.3%
High grade 1838 55.4% 1526 56.6% 246 62.6%
Unknown 913 27.5% 644 23.9% 71 18.1%
Tumor size** \0.00 \0.00
B5 cm 933 32.4% 892 38.2% 120 30.5%
[5 cm 1752 60.9% 1334 57.2% 262 66.7%
Unknown 193 6.7% 107 4.6% 11 2.8%
Depth of tumor** \0.00 0.01
Superficial 1437 45.7% 1355 52.5% 179 45.6%
Deep 1348 42.9% 996 38.6% 178 45.3%
Unknown 360 11.5% 232 9.0% 36 9.2%
Stage \0.00 –
Localized disease 2838 85.6% 2525 93.6% 393 100.0%
Distant metastases 479 14.4% 173 6.4% – –
* Excluding R2 resections, cases for which residual disease could not be determined (RX) and metastatic disease
** Excluding cases for which extent of disease (EOD) stage could be determine
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Clinical Indicators
With respect to pathology reports, sarcoma subtype
remained unknown in 20% of patients, tumor grade in 28%
(when restricted to the subset of liposarcoma, fibrosarcoma,
and leiomyosarcoma cases: 24%) and resection status in 24%
(Table 3). High-volume pathology laboratories (compared
with low-volume) and those located in academic hospitals
(compared to those in general hospitals) and sarcoma research
centers (compared with those in other hospitals) performed
better in reporting tumor grade, resection status, whereas no
difference was observed for reporting sarcoma subtype.
Following adjustment for case mix factors, resection rates
of deep or large tumors without prior histopathologic con-
firmation seemed considerably higher in low-volume
hospitals, general hospitals, and nonsarcoma research
centers. In academic hospitals and sarcoma research centers,
a larger proportion of operations comprised R1 resections.
The odds for sarcoma patients to receive radiotherapy
appeared higher when surgery was performed in high-
volume hospitals, academic hospitals, and sarcoma
research centers. The same was true regarding adjuvant
radiotherapy following R1 resection, although this effect
was no longer significant between academic and general
hospitals after adjustment for case mix factors. No differ-
ences in 5-year overall survival rates were detected
between hospital categories.
DISCUSSION
This survey indicates a need for improving STS care in
the Netherlands, both in acquisition and reporting accurate
TABLE 2 STS subtypes diagnosed in adult patients (C18 years) in the Netherlands during the time period 2006–2011
Sarcoma subtype (WHO 2002) Total Median age
(interquartile range)
Male/female
n % Year %/%
Liposarcoma 668 20.1 60 (49–71) 59.6/40.4
Well-differentiated liposarcoma 256 7.7 61 (53–71) 58.6/41.4
Myxoid liposarcoma 158 4.8 46 (37–60) 57.0/43.0
Round cell liposarcoma 10 0.3 47 (44–52) 90.0/10.0
Pleomorphic liposarcoma 48 1.4 67 (60–76) 58.3/41.7
Dedifferentiated liposarcoma 150 4.5 65 (56–73) 59.3/40.7
Mixed-type liposarcoma 8 0.2 65 (48–74) 75.0/25.0
Liposarcoma nos 38 1.1 70 (57–79) 68.4/31.6
Fibrosarcoma 381 11.5 65 (55–76) 55.6/44.4
Well-differentiated fibrosarcoma 83 2.5 60 (48–74) 45.8/54.2
Conventional fibrosarcoma 66 2.0 65 (57–77) 56.1/43.9
Poorly differentiated fibrosarcoma 135 4.1 68 (61–80) 56.3/43.7
Fibrosarcoma nos 97 2.9 64 (48–75) 62.9/37.1
Leiomyosarcoma 701 21.1 64 (53–75) 56.5/43.5
Well-differentiated leiomyosarcoma 148 4.5 61 (50–73) 58.8/41.2
Conventional leiomyosarcoma 180 5.4 64 (53–75) 55.0/45.0
Poorly differentiated/plesiomorphic/epithelioid leiomyosarcoma 137 4.1 64 (57–75) 51.8/48.2
Leiomyosarcoma nos 236 7.1 67 (54–76) 58.9/41.1
Rhabdomyosarcoma 91 2.7 56 (42–65) 67.0/33.0
(Embryonal) rhabdomyosarcoma 40 1.2 53 (35–64) 75.0/25.0
Alveolar rhabdomyosarcoma 13 0.4 26 (21–42) 53.8/46.2
Pleomorphic rhabdomyosarcoma 38 1.1 63 (54–71) 63.2/36.8
Epithelioid hemangioendothelioma 15 0.5 48 (36–59) 40.0/60.0
Angiosarcoma 199 6.0 68 (61–79) 33.2/66.8
Synovial sarcoma 111 3.3 45 (32–59) 55.0/45.0
Malignant peripheral nerve sheath tumor (MPNST) 165 5.0 50 (36–67) 55.8/44.2
Malignant fibrous histiocytoma (MFH)/pleomorphic
undifferentiated sarcoma (PUS)
338 10.2 71 (60–81) 54.7/45.3
Other sarcoma 648 19.5 64 (49–76) 54.5/45.5
Total 3317 100.0 63 (50–75) 55.2/44.8
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diagnostic information and providing optimal STS treat-
ment. Important STS tumor characteristics remained
unmentioned in one-fifth of the pathology reports. The
diagnostic workup of large or deeply located STS was
incomplete in almost one-third. More than half of patients
did not receive the required adjuvant radiation. This does
not preclude, however, that patients and physicians may
have opted for active surveillance to monitor the tumor’s
biological behavior, provided that salvage surgery could be
performed in the event of a recurrence.
For particular indicators (grade, resection status,
‘‘whoops’’ resection, and delivery of radiotherapy), out-
comes were better when diagnostic and treatment occurred
in high-volume hospitals, academic hospitals, and sarcoma
research centers compared with other hospitals. Surgery in
high-volume hospitals less often resulted in R2 resections.
The introduction of evidence-based national STS guideli-
nes produced little effect in contrast to bone sarcoma
guidelines.25 Compliance to these guidelines was mostly
moderate, particularly in smaller hospitals.14 Earlier sur-
veys performed in France and the UK also showed
disappointing compliance rates regarding STS guidelines,
with overall estimates approximating 50% at best, and rates
having remained fairly constant over time. 26–30 Such sit-
uations do appear to be successfully ameliorated by
regional initiatives, for instance directed at improving the
quality of pathology reports.13
To be sure, strict conformity to guidelines far from
qualifies as optimal STS care. For instance, to preserve
functionality of limbs affected by STS, positive margins
may be justifiable.31 This would explain our
counterintuitive finding that R1 resections more often
occurred in academic hospitals and in sarcoma research
centers: an R1 resection oftentimes represents the only
treatment option for locally advanced STS.32 In case of
residual disease, irrespective of it being microscopic or
macroscopic cancer, an attempt to obtain adequate margins
through reexcision should be evaluated, and the same holds
for administration of adjuvant multimodality therapy. As
for the observed omittance of adjuvant radiotherapy fol-
lowing an R1 resection, we could not rule out that wait-
and-see policies were in fact pursued in such cases. In
addition, treatment may have been withheld for both dis-
ease and patient-related factors (performance status,
comorbidity).33
These considerations point to the limitations of this
survey, the lack of information on patients’ performance
status and comorbidities, the intent of treatment provided
as well as the reasons for treatment omittance. As a con-
sequence, case mix corrections may not have adequately
accounted for the full variance of baseline characteristics
across different hospital categories. Also, we were not able
to conclusively infer from the cancer registry data whether
resections without prior histopathologic confirmation
indeed concerned unplanned excisions (‘‘whoops’’ proce-
dures). In addition, because no central pathology review
was performed, misdiagnosed cases may have been inclu-
ded in the analyses. Nevertheless, the results seem largely
valid for assessing STS care in the Netherlands; the anal-
yses were performed on an unselected sample of Dutch
STS patients, and main outcomes are consistent with other
reports.
In describing the prospects for improving STS care,
several challenges remain important to emphasize. Most
importantly, with an incidence rate of approximately 3
cases per 100,000 inhabitants (European Standardized
Rate), STS represent a group of uncommon tumors that
show diverse presentations.1 A general practitioner in the
Netherlands encounters on average one STS patient every
twenty years and a general or orthopedic surgeon one in
every four years. At the same time, as mentioned, benign
soft-tissue tumors are more than 100 times as common as
STS.34, 35 Misdiagnosis and inadequate treatment are likely
to occur.
It is clear that optimal STS care requires extensive,
multidisciplinary expertise, and well-organized care pro-
cesses, and studies have confirmed benefit for management
in sarcoma centers, or in hospitals working within spe-
cialized, dedicated STS networks.36–39
All in all, improvements in STS care may be achieved
by having management primarily carried out in reference
centers for sarcomas. Within reference networks, centers
may share their multidisciplinary expertise and treat large
numbers of patients. In this setting, centralized referral
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should be pursued as early as possible, preferably at the
time of the clinical diagnosis of a suspected sarcoma. In
practice, referral of all patients with a lesion likely to be a
sarcoma would be recommended. This would mean refer-
ring all patients with an unexplained deep mass of soft
tissues, or with a superficial lesion of soft tissues having a
diameter of[5 cm.17 Although more centralized manage-
ment may come with the cost of large numbers of patients
being redirected to centers for benign abnormalities,
potentially causing delayed treatment of those with proven
STS, some have reported encouraging outcomes for more
stringent referral patterns.40,41 In the Netherlands, national
referral guidelines are already well-established for bone
sarcoma.
While specific criteria for reference centers may vary
from country to country, centralizing STS care should be
based, among others, on the availability of state-of-the-art
facilities for STS diagnostics and treatment, multidisci-
plinary expertise (employed in weekly tumor boards
discussing new patients, for instance), and larger volumes
of patients. Quality of STS care delivered should be
monitored and outcomes reported on a regular basis. Also,
centers are involved in ongoing clinical trials, for which
patients’ enrollment is common.
In the Netherlands, centralizing STS care in five dedi-
cated sarcoma centers, in analogy with the four national
bone sarcoma centers, may enhance the development and
implementation of new diagnostics (e.g., imaging tech-
nologies and improved STS subtyping according to tumors’
molecular makeup) and therapeutic strategies (introduction
of new combined, pathway driven treatment modalities).
Moreover, restricting the number of centers should facili-
tate a nationwide pathology review and reporting standard,
and foster focused research initiatives on the mentioned
themes. Hence, centralization may prove most beneficial
for establishing disease-orientated sarcoma care, including
participation in trials, which eventually should lead not
only to more favorable clinical outcomes, but also to more
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efficient and cost-effective STS.42 It is time for integrated
sarcoma care, in the Netherlands and in Europe.43
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24.0% 0.83 0.93 (0.71–1.21) 0.56* 0.65* (0.48–0.88) 0.56* 0.65* (0.46–0.93)
Residual disease following resection
Unknown resection status** 24.0% 0.87 0.99 (0.81–1.21) 0.56* 0.70* (0.56–0.87) 0.58* 0.73* (0.57–0.94)
Microscopic residual disease (R1) excluding M1
and (retro)peritoneal tumors
20.0% 1.23 1.22 (0.95–1.57) 1.41* 1.41* (1.09–1.82) 1.53* 1.56* (1.22–2.00)
Macroscopic residual disease (R2) excluding M1
and (retro)peritoneal tumors
3.0% 1.00 0.67 (0.37–1.21) 1.24 0.76 (0.42–1.38) 1.23 0.94 (0.52–1.69)
Possible ‘‘whoops’’ resection
Resection of deep or large tumors ([5 cm)
without prior histopathologic confirmation
32.0% 0.19* 0.19* (0.15–0.24) 0.18* 0.18* (0.14–0.23) 0.22* 0.20* (0.16–0.26)
Radiotherapy excluding M1 and (retro) peritoneal tumors
No radiotherapy neoadjuvant or adjuvant 58.1% 0.39* 0.56* (0.47–0.68) 0.36* 0.53* (0.43–0.65) 0.38* 0.53* (0.43–0.64)
No adjuvant radiotherapy following R1 resection 52.6% 0.43* 0.50* (0.31–0.80) 0.46* 0.56* (0.35–0.90) 0.42* 0.47* (0.29–0.74)
Crude Adjusted*** Crude Adjusted*** Crude Adjusted***
% HR HR 95%CI HR HR 95% CI HR HR 95%CI
Overall survival surgically treated patients, excluding low-grade and M1 disease
5-Year postdiagnosis 61.3% 1.12 1.15 (0.99–1.34) 1.15* 1.14 (0.97–1.33) 1.10 1.08 (0.93–1.27)
CI confidence interval; OR odds ratio
* Statistically significant (p\ 0.05)
** Comparison is calculated on the level of pathology laboratory
*** Additionally adjusted for adjuvant treatment
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